TAILIEUCHUNG - HORMONE THERAPY IN BREAST AND PROSTATE CANCER

It has been said that the control of disease has three goals, which, in increasing order of attraction are palliation, cure, and prevention. For most types of disseminated cancer, medical science has achieved only the first of these objectives, while for some malignancies the side effects of the therapeutic agents employed rival the disease itself in precluding a desirable quality of life. In contrast, those cancers of the breast and prostate that retain the hormone dependency of the tissue of origin, and thus are sensitive to endocrine manipulation, offer a more favorable situation for control. Hormone Therapy in Breast and Prostate Cancer takes the reader on a fascinating. | CANCER DRŨG discovery and development r A T gí V 1 V - A 1 V y - b - - f IL a X l _ I - 11 V Hormone Therapy in B st and BPrpstate Cancer 4. r 1 _ vj _U M . Nb c - . . x- iỉ - Z- .- . . Edited by V Craig Jordan Barrington J A Furr V 51 4 J f - w f I toPKEc 1k X- J Hormone Therapy IN Breast and Prostate Cancer Cancer Drug Discovery and Development Beverly A. Teicher Series Editor Hormone Therapy in Breast and Prostate Cancer EDITED BY V. Craig Jordan and Barrington J. A. Furr 2002 Tumor Models in Cancer Research EDITED BY Beverly A. Teicher 2002 Tumor Suppressor Genes in Human Cancer EDITED BY David E. Fisher 2001 Matrix Metalloproteinase Inhibitors in Cancer Therapy EDITED BY Neil J. Clendeninn and Krzysztof Appelt 2001 Farnesyltransferase Inhibitors in Cancer and Cardiovascular Therapy EDITED BY Said M. Sebti and Andrew D. Hamilton 2001 Platinum-Based Drugs in Cancer Therapy EDITED BY Lloyd R. Kelland and Nicholas P. Farrell 2000 Signaling Networks and Cell Cycle Control The Molecular Basis of Cancer and Other Diseases EDITED BY J. Silvio Gutkind 1999 Apoptosis and Cancer Chemotherapy EDITED BY John a. Hickman and Caroline Dive 1999 Antifolate Drugs in Cancer Therapy EDITED BY Ann L. Jackman 1999 Antiangiogenic Agents in Cancer Therapy EDITED BY Beverly A. Teicher 1999 Anticancer Drug Development Guide Preclinical Screening Clinical Trials and Approval EDITED BY Beverly A. Teicher 1997 Cancer Therapeutics Experimental and Clinical Agents EDITED BY Beverly A. Teicher .

• Y học thường thức
• Cancer Chemotherapy
• Cancer Therapy
• Cancer Therapeutics
• Anticancer Drug
• Tumor Models
• Cancer Therapeutics
• BMC Cancer
• Advanced breast cancer
• Adjuvant chemotherapy
• Primary systemic chemotherapy
• Postoperative chemotherapy
• Neoadjuvant chemotherapy
• Esophageal cancer
• Despite advances
• Gastric cancer
• Palliative chemotherapy
• Combination chemotherapy
• Advanced gastric cancer
• Triplet chemotherapy
• Doublet chemotherapy
• Meta analysis
• First line chemotherapy
• Perioperative chemotherapy
• Overall survival
• Lung cancer
• Patient preferences
• Chemotherapy treatment options
• Non small cell lung cancer
• Peritoneal metastasis
• Intraperitoneal chemotherapy
• Pressurized intraperitoneal aerosol chemotherapy
• Palliative treatment
• Systemic chemotherapy
• Primary debulking surgery
• Primary peritoneal cancer
• Visible tumours despite
• Ovarian cancer
• Germline BRCA
• Chemotherapy response scores
• Metastatic setting
• Positron emission tomography
• Chemotherapy induced neutropenia
• Clinical study
• Breast Cancer
• Therapeutic equivalence
• Risk factor
• Multimodal treatment strategies
• Lymph node dissection
• FAC chemotherapy
• AC chemotherapy
• Disease free survival
• Adjuvant leukoprotective
• Metronomic chemotherapy
• Low dose chemotherapy
• Head neck cancer
• Personalized medicine
• Acute toxicities
• Head and neck cancer
• Dose dense chemotherapy
• Induction chemotherapy
• 5 fluorouracil plus docetaxel
• Preoperative chemoradiotherapy
• Adjuvant therapy
• Pancreatic cancer
• Second line chemotherapy
• Gemcitabine chemotherapy
• Therapeutics strategy
• Early breast cancer
• Quality of life
• Chemotherapy induced nausea
• Including homeopathy
• Locally advanced breast cancer
• Pathologic complete response
• Lymph node
• Tumor infiltrating lymphocytes
• Cervical cancer
• Survival outcomes
• Chemotherapy plus bevacizumab
• Chemotherapy alone
• Postmenopausal women
• Colorectal cancer
• Chemotherapy induced nausea and vomiting
• Moderate emetic risk
• Female patients
• Pegylated liposomal doxorubicin
• Conventional anthracycline
• Concurrent chemotherapy
• Triple negative breast cancer
• Doxorubicin based chemotherapy
• Residual cancer burden
• Predictive marker